Form 4: Corcept Therapeutics CFO Atabak Mokari Reports Transactions in Company Stock

Atabak Mokari, CFO of Corcept Therapeutics, reports the acquisition and disposal of company stock, including shares withheld for tax obligations and shares purchased under a company purchase plan.

Summary

• On September 3, 2024, Atabak Mokari, the CFO of Corcept Therapeutics, reported transactions involving the company's common stock.
• The transactions included the withholding of 143 shares to cover tax obligations related to the vesting of restricted stock units at a price of $35.3 per share.
• Mokari also acquired 400 shares under a purchase plan at $34.26 per share and an additional 400 shares under unvested restricted stock awards.
• Following these transactions, Mokari beneficially owns 12,518 shares of Corcept Therapeutics common stock, including unvested restricted stock awards.
• The unvested restricted stock awards include 508 shares granted on December 1, 2023, 554 shares granted on March 1, 2024, and 1,448 shares granted on June 3, 2024, all vesting on their one-year anniversary.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing. The transactions themselves don't necessarily indicate positive or negative sentiment, but rather routine activity.

Positives

• The CFO's participation in the company's purchase plan could be seen as a positive signal.

Industry Context

Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company executives and directors. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Stakeholder Impact

• The reported transactions provide transparency to shareholders regarding the CFO's stock activity.

Key Dates